Treatment of MRSA infections;Therapie von MRSA-Infektionen

Deutsche Medizinische Wochenschrift

Volumn 137, Issue 49, 2012, Pages 2553-2557

  Borde, J P ^a,b   Kern, W V ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b Klinik fur Gastroenterologie Hepatologie und Infektiologie   (Germany)

Author keywords

ceftaroline; ceftobiprole; daptomycin; Methicillin resistant Staphylococcus aureus; MRSA

Indexed keywords

ARTICLE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION;

ANTI-BACTERIAL AGENTS; ARTHRITIS, INFECTIOUS; BACTEREMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ENDOCARDITIS, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OSTEOMYELITIS; PNEUMONIA, STAPHYLOCOCCAL; PROSTHESIS-RELATED INFECTIONS; SOFT TISSUE INFECTIONS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN RESISTANCE;

EID: 84870411600     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0032-1327283     Document Type: Article

References (23)

1. Brunkhorst F. M., Gastmeier P., Kern W. et al. Prävention, Diagnose, Therapie und Nachsorge der Sepsis. 1. Revision der S-2k Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen Interdisziplinä ren Vereinigung für Intensiv- und Notfallmedizin (DIVI). Internist: 2010; 51 925 932
2. Byren I., Rege S., Campanaro E. et al. Safety and efficacy of daptomycin vs. standard-of-care therapy for the management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother: 2012; Aug 20.
3. Frei C. R., Miller M. L., Lewis J. S. 2nd et al. Trimethoprim- sulfamethoxazole or clindamycin for community-associated MRSA (CA-MRSA) skin infections. J Am Board Fam Med: 2010; 23 714 719
4. Gould F. K., Brindle R., Chadwick P. R. et al. on behalf of the MRSA Working Party of the British Society for Antimicrobial Chemotherapy Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother: 2009; 63 849 861
5. Hagihara M., Umemura T., Mori T. et al. Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus. Ther Clin Risk Manag: 2012; 8 79 86
6. Ho T. T., Cadena J., Childs L. M. et al. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother: 2012; 67 1267 1270
7. John A. K., Baldoni D., Haschke M. et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother: 2009; 53 2719 2724
8. Jung Y. J., Koh Y., Hong S. B. et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med: 2010; 38 175 180
9. Köck R., Mellmann A., Schaumburg F. et al. The epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) in Germany. Dtsch Arztebl Int: 2011; 108 761 767
10. Kullar R., Davis S. L., Levine D. P. et al. High-dose daptomycin for treatment of complicated gram-positive infections. Pharmacotherapy: 2011; 31 527 536
11. Kullar R., Davis S. L., Taylor T. N. et al. Effects of targeting higher vancomycin trough levels on clinical outcomes and costs in a matched patient cohort. Pharmacotherapy: 2012; 32 195 201
12. Lin J. C., Aung G., Thomas A. et al. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections. J Infect Chemother: 2012; Jul 14.
13. Liu C., Bayer A., Cosgrove S. E. et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis: 2011; 52 285 292
14. Moore C. L., Osaki-Kiyan P., Haque N. Z. et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis: 2012; 54 51 58
15. Paul-Ehrlich-Gesellschaft P-E-G Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen - Update 2010.
16. Rivera A. M., Boucher H. W. Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci and vancomycin-resistant enterococci. Mayo Clin Proc: 2011; 86 1230 1243
17. Rodriguez C. A., Agudelo M., Zuluaga A. F. et al. Generic vancomycin enriches resistant subpopulations of Staphylococcus aureus after exposure in a neutropenic mouse thigh infection model. Antimicrob Agents Chemother: 2012; 56 243 247
18. Saleh-Mghir A., Dumitrescu O., Dinh A. et al. Ceftobiprole efficacy in vitro on panton-valentine leukocidin production and in vivo in rabbit community-associated methicillin-resistant Staphylococcus aureus osteomyelitis. Antimicrob Agents Chemother: 2012; Oct 1.
19. Saleh-Mghir A., Muller-Serieys C., Dinh A. et al. Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother: 2011; 55 4589 4593
20. Schöfer H., Bruns R., Effendy I. et al. Diagnosis and treatment of Staphylococcus aureus infections of the skin and mucous membranes. J Dtsch Dermatol Ges: 2011; 9 953 967
21. Takesue Y., Nakajima K., Takahashi Y. et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother: 2011; 17 52 57
22. Verrall A. J., Llorin R., Tam V. H. et al. Efficacy of continuous infusion of vancomycin for the outpatient treatment of methicillin-resistant Staphylococcus aureus infections. J Antimicrob Chemother: 2012; Aug 21.
23. Wunderink R. G., Niederman M. S., Kollef M. H. et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Clin Infect Dis: 2012; 54 621 629